Although progression-based endpoints, such as progression-free survival, are often key
clinical trial endpoints for anticancer agents, the clinical meaning of “objective progression” …

A sensitive and convenient method for detecting epidermal growth factor receptor (EGFR)
T790M mutations from circulating tumor DNA (ct DNA) in advanced non–small cell lung …

Lung cancer is a heterogeneous, complex, and challenging disease to treat. With the arrival
of genotyping and genomic profiling, our simple binary division of lung cancer into non-small …

Purpose. Epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer has
an oncogene‐addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors …

Abstract Objectives Although T790M mutation is considered to be the major mechanism of
acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …

Introduction Approximately 50% of lung cancer patients with epidermal growth factor
receptor (EGFR)-mutations (deletion in exon 19 or L858R) who develop acquired resistance …

Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from
human plasma, serum and other body fluids. Circulating tumor DNA shed from primary and …

Simple Summary Leptomeningeal metastases are a devastating complication of solid
tumors with poor survival, regardless of the type of treatments. The limited efficacy of …

Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …

Background: Accumulating data shows that exon 19 deletions and L858R, both activating
epidermal growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are …